Literature DB >> 7525035

Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.

S Murakami1, A Satomi, K Ishida, H Murai, M Matsuki, T Hashimoto.   

Abstract

BACKGROUND: Serum concentrations of soluble interleukin-2 receptor (IL-2R) were found to be high in patients with autoimmune diseases, lung cancer, malignant lymphoma, tuberculosis, and other diseases. Serum-soluble IL-2R was evaluated as a tumor maker in patients with gastric cancer.
METHODS: Preoperative concentrations of serum-soluble IL-2R were examined in 40 patients with gastric cancer. The authors investigated the correlations of serum-soluble IL-2R concentrations with various characteristics of this cancer (disease stage, gross appearance, depth of the tumor, lymph node metastasis, liver metastasis, peritoneal metastasis, histopathologic grade, serum carcinoembryonic antigen (CEA), alpha-fetoprotein (alpha-FTP), carbohydrate antigen 19-9 (CA19-9), and immunosuppressive acidic protein (IAP). Serum soluble IL-2R concentrations were measured with an enzyme-linked immunosorbent assay.
RESULTS: Levels of serum-soluble IL-2R in patients with gastric cancer were significantly higher than those of normal control subjects. Serum concentrations of IL-2R in patients with lymph node metastasis were also significantly higher than those of patients without lymph node metastasis. There were no significant differences in histopathologic findings (grade, lymphatic invasion, venous invasion). Moreover, serum concentrations of soluble IL-2R in patients who were IAP positive were significantly higher than those who were IAP negative.
CONCLUSIONS: Preoperative serum-soluble IL-2R concentrations in patients with gastric cancer reflect the occurrence of regional lymph node metastases. Preoperative evaluation of serum soluble IL-2R concentrations may be a valuable parameter of indicating the probability of lymph node metastasis preoperatively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525035     DOI: 10.1002/1097-0142(19941115)74:10<2745::aid-cncr2820741002>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer.

Authors:  H Saito; S Tsujitani; K Katano; M Ikeguchi; M Maeta; N Kaibara
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

2.  Relation between depression and circulating immune products in patients with advanced colorectal cancer.

Authors:  T G Allen-Mersh; C Glover; C Fordy; D C Henderson; M Davies
Journal:  J R Soc Med       Date:  1998-08       Impact factor: 5.344

3.  Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions.

Authors:  Jun Murakami; Kotaro Arita; Akinori Wada; Hiroshi Mihara; Hideki Origasa; Mika Kigawa; Ichiro Yasuda; Tsutomu Sato
Journal:  Mol Clin Oncol       Date:  2019-09-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.